Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amsurg to acquire Sheridan Healthcare in transformational transaction valued at $2.35 bln


Thursday, 29 May 2014 06:00am EDT 

Amsurg Corp:To acquire Sheridan Healthcare in a cash and stock transaction valued at about $2.35 bln.Transaction is expected to close in the third quarter of 2014.Citi is serving as financial advisor to AMSURG and Bass, Berry & Sims PLC is providing legal counsel.Barclays, Credit Suisse and Goldman, Sachs & Co. are serving as financial advisors to Sheridan and Simpson Thacher & Bartlett LLP is providing legal counsel.Transaction is expected to close in the third quarter of 2014. 

Company Quote

51.86
0.39 +0.76%
26 Nov 2014